Meanwhile, in case Novo Nordisk can’t convince regulators of oral semaglutide’s merits first time around, it has a large-scale cardiovascular outcome study called SOUL in preparation that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback